NDAORALTABLETPriority Review
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Mechanism of Action
agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic…
Clinical Trials (5)
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
Started Oct 2006
320 enrolled
Osteoporosis, Postmenopausal
Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy
Started Sep 2006
114 enrolled
Osteoporosis
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
Started Nov 2004
200 enrolled
Postmenopausal Osteoporosis
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Started Feb 2004
500 enrolled
Osteopenia
Long Term Effects of Raloxifene Treatment on Bone Quality
Started Apr 2003
31 enrolled
Osteoporosis, Post-Menopausal